GlaxoSmithKline GSK releases its next round of earnings Wednesday. Get the latest predictions in Benzinga's essential guide to the company's Q2 earnings report.
Earnings and Revenue
Based on management's projections, GlaxoSmithKline analysts model for earnings of 78 cents per share on sales of $9.7 billion.
GlaxoSmithKline reported a profit of 35 cents when it published results during the same quarter last year. Sales in that period totaled $9.44 billion. The analyst consensus estimate would represent a 122.86 percent increase in the company's EPS figure. Revenue would be up 2.72 percent from the same quarter last year. In comparison to analyst estimates in the past, here's how the company's reported EPS stacks up:
| Quarter | Q1 2018 | Q4 2017 | Q3 2017 | Q2 2017 |
| EPS Estimate | 0.69 | 0.66 | 0.83 | 0.7 |
| EPS Actual | 0.34 | 0.35 | 0.42 | 0.35 |
Stock Performance
Over the last 52-week period, shares are down 4.03 percent. Given that these returns are generally negative, long-term shareholders are probably down going into this earnings release. Analysts have adjusted their estimates higher for EPS and revenues over the past 90 days. Analysts generally rate GlaxoSmithKline stock as Neutral. The strength of this rating has maintained conviction over the past three months.
Conference Call
GlaxoSmithKline is scheduled to hold a conference call at 8:00 a.m. ET and it can be accessed here: https://www.gsk.com/en-gb/investors/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
